sellWeak cluster of 210b5-1 plan
Phillip Samayoa sold $3,961 of GBIO
CHIEF STRATEGY OFFICER at Generation Bio Co.. 2,445 shares at an average of $1.62, traded Jan 2, 2024, filed Jan 3, 2024.
Warning score
3Value
$3,961
2,445 shares
Holdings after
107,256
-2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- 0Trade size$4k at market
- 0Share of holdings soldSold 2.2% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-24-000303, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 2, 2024 | SOpen-market sale Common Stock10b5-1 | -2,445 | $1.62 | $3,961 | 107,256 | Jan 3, 2024 |
| Jan 2, 2024 | AGrant or award Stock Option (right to buy)derivative10b5-1 | +160,650 | $0.00 | $0 | 160,650 | Jan 3, 2024 |
Related signals
Other insiders at Generation Bio Co. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 37Weak | GBIObuy Generation Bio Co. | Anthony G. Quinn director | $203k 210,791 shares | +238% | |
| 18Weak | Generation Bio Co. | Antoinette Paone CHIEF OPERATING OFFICER | $3,961 2,445 shares | -30% | |
| 45Moderate | Generation Bio Co. | Dannielle Appelhans director | $14k 8,000 shares | +67% | |
| 38Weak | Generation Bio Co. | Dannielle Appelhans director | $18k 12,000 shares | - | |
| 51Moderate | Generation Bio Co. | Donald William Nicholson director | $144k 100,000 shares | +88% | |
| 48Moderate | Generation Bio Co. | Anthony G. Quinn director | $125k 88,495 shares | - | |
| 58Moderate | Generation Bio Co. | Charles A Rowland Jr director | $478k 342,960 shares | +179% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.